This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- Lumateperone has high binding affinity for serotonin 5-HT2A receptors (Ki=0.54 nM) and moderate binding affinity for dopamine D2 (Ki=32 nM) receptors.1
- Vanover et al (2019)2 conducted an open-label (OL), positron emission tomography (PET) study to evaluate dopamine D2 receptor occupancy (D2RO) at plasma steady state following 2 weeks of treatment with 42 mg of CAPLYTA daily in the morning in patients with schizophrenia (N=10).
- Following administration of a CAPLYTA dose of 42 mg, the highest D2RO level in the dorsal striatum was observed 1 hour after dosing, with a mean±standard deviation (SD) occupancy of 39%±12% (n=6).
- Abdel Mageed et al (2025)3 investigated the procognitive effects of lumateperone 10 mg/kg/day in a ketamine-induced schizophrenia-like rat model. Lumateperone 10 mg/kg/day increased serotonin levels and phosphorylation of phosphoinositide 3-kinases (PI3K), protein kinase B (Akt), and glycogen synthase kinase-3 beta (GSK-3), and reduced 5-hydroxyindoleacetic acid (5-HIAA), the 5-HIAA/5-HT ratio, dopamine levels, 5-HT1A and 5-HT2A receptor expression relative to the ketamine group.3
- Chen et al (2026)4 evaluated the effects of lumateperone and other D₂ receptor agents on levels of haloperidol-induced phosphorylated tyrosine hydroxylase (p-TH) in the stratum of adult C57BL/6 male mice; haloperidol increased p-TH at S40 ~3-fold (P<0.001), while coadministration with lumateperone (3 or 6 mg/kg), quinpirole, and D₂ partial agonists reduced haloperidol-induced p-TH, with statistically significant reductions reported for lumateperone, quinpirole, and cariprazine.
PRODUCT LABELING
Mechanism of Action
The mechanism of action of lumateperone for the treatment of schizophrenia in adults, for the treatment of depressive episodes associated with bipolar depression (as monotherapy or as adjunctive therapy with lithium or valproate), and as adjunctive therapy with antidepressants for the treatment of major depressive disorder is unknown. However, the mechanism of action of lumateperone for these uses could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.1
Pharmacodynamics
Lumateperone has high binding affinity for serotonin 5-HT2A receptors (Ki=0.54 nM) and moderate binding affinity for dopamine D2 (Ki=32 nM) receptors.1
CLINICAL DATA
Vanover et al (2019)2 conducted an OL, PET study to evaluate the D2RO at plasma steady state following 2 weeks of treatment with 42 mg of CAPLYTA daily in the morning in patients with schizophrenia (N=10; mean age, 39.3 years). All enrolled patients discontinued their previous antipsychotic medication to establish a drug-free baseline using a 2-week washout period. During the study, 9 patients received lorazepam as a concomitant psychotropic medication.
D2RO Following CAPLYTA Treatment
- Following administration of a CAPLYTA dose of 42 mg, the highest D2RO level in the dorsal striatum was observed at 1 hour, with a mean±SD occupancy of 39%±12% (n=6).
- The mean±SD dorsal striatal D2RO gradually decreased from 34%±8% at 3 to 4 hours after dosing to 19%±10% at 7.5 hours after dosing, and 7%±7% at 24 to 27 hours after dosing (n=4).
- Combined data from all patients at 1 or 3 hours revealed a mean D2RO of 37%, with an associated mean total plasma level of 49.3 ng/mL. A statistically significant correlation was observed between D2RO and total plasma concentration (r2=0.6; P=0.0077).
Abdel Mageed et al (2025)3 investigated the procognitive effects of lumateperone 10 mg/kg/day in ketamine-induced schizophrenia-like rat model (N=40; n=10 each in control, ketamine, lumateperone, and Wortmannin groups).
- Lumateperone 10 mg/kg/day in ketamine-induced rats increased the serotonin levels by 3.7-fold (P<0.0001) and reduced 5-HIAA, the 5-HIAA/5-HT ratio, and dopamine levels by 58%, 86%, and 59%, respectively (P<0.0001, each) compared to the ketamine group.
- Lumateperone 10 mg/kg/day reduced SERT expression by 79% (vs control) and reduced the ketamine-induced increase in 5-HT1A and 5-HT2A expressions by 55% and 61%, respectively (P<0.0001, each).
- In a molecular docking analysis of 5-HT1A receptor binding, lumateperone had a docking score of -14.8 kcal/mol, compared with -9.9 kcal/mol for serotonin.
- In rats receiving lumateperone 10 mg/kg/day the phosphorylation levels of PI3K, Akt, and GSK-3 increased by 4.9-fold (P<0.0001), 3.8-fold (P<0.001), and 4.6-fold (P<0.001), respectively, relative to the ketamine group.
Chen et al (2026)4 investigated whether lumateperone, acting as a presynaptic partial agonist, reduces haloperidol-induced p-TH levels in the mouse striatum. Adult C57BL/6 male mice received an intraperitoneal injection of haloperidol (1 mg/kg) or vehicle, along with a dopamine D₂ receptor agonist quinpirole (1 or 2 mg/kg), partial agonist (aripiprazole [3 mg/kg], cariprazine [3 mg/kg], brexpiprazole [10 mg/kg], or lumateperone [6 mg/kg]), or antagonist (lurasidone hydrochloride [1 or 3 mg/kg] or quetiapine fumerate [5 or 10 mg/kg]).
- Haloperidol induced an ~3-fold increase in p-TH at the regulatory S40 residue (P<0.001); coadministration with lumateperone 3 mg/kg (P<0.01) or 6 mg/kg reduced p-TH levels versus haloperidol alone.
- Like lumateperone, quinpirole coadministration with haloperidol (vs haloperidol alone) significantly reduced haloperidol-induced p-TH (P<0.05), while quinpirole alone did not affect basal p-TH levels.
- Similar to the effect of lumateperone, aripiprazole, brexpiprazole, and cariprazine reduced haloperidol-induced TH phosphorylation, with a statistically significant reduction reported for cariprazine (P<0.0001).
LITERATURE SEARCH
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 13 October 2026.
| 1 | CAPLYTA (lumateperone) [Prescribing Information]. Titusville, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf |
| 2 | Vanover KE, Davis RE, Zhou Y, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598-605. |
| 3 | Abdel-Mageed SS, Mangoura SA, Nassar NN, et al. Role of PI3K/Akt axis in cognitive impact of lumateperone in schizophrenia rat model induced by ketamine. Int Immunopharmacol. 2025;10(167):115681. |
| 4 | Chen M, Snyder GL, Dutheil S. Assessment of lumateperone partial agonist activity at presynaptic dopamine D2 autoreceptors: reversal of haloperidol-induced tyrosine hydroxylase phosphorylation in mouse striatum. Poster presented at: Psych Congress 2026; September 15-19, 2026; New Orleans, LA, USA. |